Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akira Nishio

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Gastro Hep Advances|January 16, 2026
Gas-forming Pyogenic Liver Abscess Mimicking Gastric Perforation in a Patient With Diabetic Ketoacidosis and Subsequent Rupture: A Case ReportTairyu Sato, Koki Yamada, Akira Nishio, et al.
Plos One|December 21, 2022
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosisKumiko Shirai, Hayato Hikita, Ryotaro Sakamori, et al.
Journal for Immunotherapy of Cancer|March 30, 2026
Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinomaAkira Nishio, Takahiro Kodama, Kazuma Daiku, et al.
Cancers|January 21, 2023
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting AntiviralTakayuki Matsumae, Takahiro Kodama, Yuki Tahata, et al.
Plos Pathogens|May 12, 2017
Characterization of miR-122-independent propagation of HCVChikako Ono, Takasuke Fukuhara, Daisuke Motooka, et al.
Gastro Hep Advances|January 26, 2026
Contrast-Enhanced Ultrasound and Somatostatin Receptor Scintigraphy Unveil an Occult Neuroendocrine Tumor With Carcinoid Syndrome and Presumed Small Intestinal Origin - A Case ReportTairyu Sato, Akira Nishio, Tadashi Kegasawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 18, 2024
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogsEmi Sometani, Hayato Hikita, Kazuhiro Murai, et al.
BMC Gastroenterology|May 1, 2026
Improvement of hepatic reserve and changes in liver and spleen volume after balloon-occluded retrograde transvenous obliterationKazuma Shinkai, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology (Baltimore, Md.)|January 15, 2026
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinomaShuhei Yamamoto, Takahiro Kodama, Akifumi Kuwano, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabYu Sato, Takahiro Kodama, Kazuki Maesaka, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Gastro Hep Advances|January 16, 2026
Gas-forming Pyogenic Liver Abscess Mimicking Gastric Perforation in a Patient With Diabetic Ketoacidosis and Subsequent Rupture: A Case ReportTairyu Sato, Koki Yamada, Akira Nishio, et al.
Plos One|December 21, 2022
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosisKumiko Shirai, Hayato Hikita, Ryotaro Sakamori, et al.
Journal for Immunotherapy of Cancer|March 30, 2026
Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinomaAkira Nishio, Takahiro Kodama, Kazuma Daiku, et al.
Cancers|January 21, 2023
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting AntiviralTakayuki Matsumae, Takahiro Kodama, Yuki Tahata, et al.
Plos Pathogens|May 12, 2017
Characterization of miR-122-independent propagation of HCVChikako Ono, Takasuke Fukuhara, Daisuke Motooka, et al.
Gastro Hep Advances|January 26, 2026
Contrast-Enhanced Ultrasound and Somatostatin Receptor Scintigraphy Unveil an Occult Neuroendocrine Tumor With Carcinoid Syndrome and Presumed Small Intestinal Origin - A Case ReportTairyu Sato, Akira Nishio, Tadashi Kegasawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 18, 2024
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogsEmi Sometani, Hayato Hikita, Kazuhiro Murai, et al.
BMC Gastroenterology|May 1, 2026
Improvement of hepatic reserve and changes in liver and spleen volume after balloon-occluded retrograde transvenous obliterationKazuma Shinkai, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology (Baltimore, Md.)|January 15, 2026
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinomaShuhei Yamamoto, Takahiro Kodama, Akifumi Kuwano, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabYu Sato, Takahiro Kodama, Kazuki Maesaka, et al.
Pageof 6